Follow
Christina Lamers
Christina Lamers
Verified email at uni-leipzig.de - Homepage
Title
Cited by
Cited by
Year
Revealing the macromolecular targets of complex natural products
D Reker, AM Perna, T Rodrigues, P Schneider, M Reutlinger, B Mönch, ...
Nature chemistry 6 (12), 1072-1078, 2014
1292014
Macrocyclization strategies for cyclic peptides and peptidomimetics
C Bechtler, C Lamers
RSC Medicinal Chemistry 12 (8), 1325-1351, 2021
792021
Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)
C Lamers, M Schubert-Zsilavecz, D Merk
Expert opinion on therapeutic patents 22 (7), 803-841, 2012
722012
Molecular tuning of farnesoid X receptor partial agonism
D Merk, S Sreeramulu, D Kudlinzki, K Saxena, V Linhard, SL Gande, ...
Nature communications 10 (1), 2915, 2019
692019
Nonacidic farnesoid X receptor modulators
D Flesch, SY Cheung, J Schmidt, M Gabler, P Heitel, J Kramer, A Kaiser, ...
Journal of Medicinal Chemistry 60 (16), 7199-7205, 2017
682017
Extending the structure–activity relationship of anthranilic acid derivatives as Farnesoid X receptor modulators: Development of a highly potent partial Farnesoid X receptor …
D Merk, C Lamers, K Ahmad, R Carrasco Gomez, G Schneider, ...
Journal of Medicinal Chemistry 57 (19), 8035-8055, 2014
572014
Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
J Wilbs, XD Kong, SJ Middendorp, R Prince, A Cooke, CT Demarest, ...
Nature communications 11 (1), 3890, 2020
532020
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators
R Blöcher, C Lamers, SK Wittmann, D Merk, M Hartmann, L Weizel, ...
Journal of medicinal chemistry 59 (1), 61-81, 2016
502016
The promiscuous profile of complement receptor 3 in ligand binding, immune modulation, and pathophysiology
C Lamers, CJ Plüss, D Ricklin
Frontiers in immunology 12, 662164, 2021
482021
Compstatins: the dawn of clinical C3-targeted complement inhibition
C Lamers, DC Mastellos, D Ricklin, JD Lambris
Trends in Pharmacological Sciences 43 (8), 629-640, 2022
382022
Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists
C Lamers, M Schubert-Zsilavecz, D Merk
Current topics in medicinal chemistry 14 (19), 2188-2205, 2014
352014
Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)
D Merk, M Gabler, RC Gomez, D Flesch, T Hanke, A Kaiser, C Lamers, ...
Bioorganic & medicinal chemistry 22 (8), 2447-2460, 2014
352014
Overcoming the shortcomings of peptide-based therapeutics
C Lamers
Future Drug Discovery 4 (2), FDD75, 2022
322022
Anthranilic acid derivatives as nuclear receptor modulators—Development of novel PPAR selective and dual PPAR/FXR ligands
D Merk, C Lamers, J Weber, D Flesch, M Gabler, E Proschak, ...
Bioorganic & medicinal chemistry 23 (3), 499-514, 2015
322015
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
E Buscató, R Blöcher, C Lamers, FM Klingler, S Hahn, D Steinhilber, ...
Journal of medicinal chemistry 55 (23), 10771-10775, 2012
292012
Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition
T Hanke, C Lamers, RC Gomez, G Schneider, O Werz, ...
Bioorganic & medicinal chemistry letters 24 (16), 3757-3763, 2014
152014
Novel prostaglandin receptor modulators–Part II: EP receptor modulators; a patent review (2002–2012)
D Flesch, D Merk, C Lamers, M Schubert-Zsilavecz
Expert opinion on therapeutic patents 23 (2), 233-267, 2013
152013
Novel prostaglandin receptor modulators: a patent review (2002–2012)–part I: non-EP receptor modulators
C Lamers, D Flesch, M Schubert-Zsilavecz, D Merk
Expert opinion on therapeutic patents 23 (1), 47-77, 2013
122013
Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery
C Lamers, D Ricklin, JD Lambris
American Journal of Hematology 98, S82-S89, 2023
112023
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors
C Lamers, X Xue, M Smieško, H van Son, B Wagner, N Berger, G Sfyroera, ...
Nature Communications 13 (1), 5519, 2022
102022
The system can't perform the operation now. Try again later.
Articles 1–20